Novo Nordisk Shares Climb on Dual Tailwinds, but Data Gaps and Cost Concerns Keep Bulls in Check
Published on 07/20/2026 at 14:52 | Redaktion boerse-global.de
Novo Nordisk’s stock has clawed back ground from its March lows, powered by two distinct catalysts: a newly approved oral version of Wegovy in Europe and expanded Medicare coverage for its GLP-1 drugs in the U.S. Yet for all the recent momentum, analysts and market data suggest the rally rests more on promise than proof — leaving investors to weigh a familiar gap between market potential and real-world uptake.
The Danish drugmaker’s shares traded at €44.39 on the day of the latest update, up 1.0%, and have risen 12.32% over the past 30 days. That still leaves the stock 21.19% below its level a year ago and 27.17% shy of the 52-week high of €60.95 touched in July 2025. From the March 2 low of €30.25, the recovery amounts to 46.74%. Deutsche Bank, however, has held its ground: analyst Emmanuel Papadakis kept a "Hold" rating and a price target of DKK 290, signaling that the bank sees the recent advance as anticipation rather than confirmation of a demand surge.
The EU green light for Wegovy in tablet form, granted on July 15, marks the first GLP-1 obesity treatment available as a pill in Europe. The convenience of a daily tablet over a weekly injection could broaden the addressable market, boosting adherence and attracting patients who avoid needles. To support supply, Novo Nordisk has started production at a new $360 million facility in Czechia, and a cheaper Ozempic variant called Extensior is set to launch in South Africa on July 27. These moves aim to tackle past capacity constraints and expand into emerging markets.
Simultaneously, the U.S. Medicare program’s GLP-1 Bridge — effective July 1 — caps patient co-pays for Wegovy and rival Zepbound at $50 per month through end-2027. A study from the USC Schaeffer Center, published July 9 in the American Journal of Managed Care, found that after Wegovy was approved for heart-disease prevention in March 2024, Medicare prescriptions surged 598% in absolute terms and 136% on a per-prescription basis. Yet fewer than 1% of the 3.6 million eligible beneficiaries have actually filled a prescription — underscoring a chasm between eligibility and action. Deutsche Bank notes that while the expectation of a Medicare-driven boost likely fueled the recent rally, hard evidence of a script uptick has not yet materialized.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Optimists point to the stock’s technical setup: it has broken above both its 50-day moving average of €40.11 and its 200-day average of €40.46, with a relative strength index of 61.5 — bullish but not overbought. A sustained move higher would need the 200-day line to hold as support, followed by concrete sales data. The next major test comes with the Extensior rollout on July 27 and the quarterly earnings report due August 5.
Skeptics, however, see clouds on multiple fronts. A cost-effectiveness model in JAMA Health Forum estimates that expanding Medicare GLP-1 coverage would add $48 billion in net spending over a decade. The Institute for Clinical and Economic Review pegged lifetime drug costs for semaglutide at $274,000 against just $62,000 in savings, with a cost of $468,000 per quality-adjusted life year — far above the typical $100,000 threshold. A broad meta-analysis in the BMJ, covering nearly 100,000 participants across 262 studies, also found that weight loss from semaglutide and tirzepatide does not reliably translate into improved quality of life, and greater weight loss correlates with more side effects.
Competition adds another layer of risk. Eli Lilly is advancing its own oral and injectable GLP-1 candidates, potentially squeezing prices and margins. Regulatory pressure on drug pricing remains a concern, and quality issues at the recently acquired Bloomington site could disrupt production. The stock’s year-to-date decline of roughly 0.50% reflects lingering market skepticism over whether high list prices can hold.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
For now, Novo Nordisk’s narrative hinges on whether the theoretical demand from Medicare and the convenience of an oral Wegovy can harden into measurable prescription growth. If the August earnings show rapid uptake in both the U.S. and early European markets, a move back toward the €60.95 peak is plausible. If not, renewed price competition or supply snags could pull the stock back to the 50-day average near €40.11. The data, not the hope, will decide.
Ad
Novo Nordisk Stock: New Analysis - 20 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
